

Index

- ABCB7* sideroblastic anemia, 266–8
 clinical description, 267
 genetics, 267–8
 history, 267
 laboratory findings, 267
 prevention and treatment, 268
- aceruloplasminemia, 1, 5, 41
- aconitase, 14
- acquired atransferrinemia, 225–6
 antitransferrin antibodies, 225–6
 nephrotic syndrome, 225
- acquired sideroblastic anemias, 277–81
 alcohol-induced, 280
 anti-tuberculosis drugs, 279
 cancer chemotherapy, 281
 characteristics, 277
 chloramphenicol, 280
 classification, 277
 copper deficiency and zinc excess, 280
 immunosuppressive drugs, 281
 lead intoxication, 279–80
 myelodysplastic syndromes, 277–9
 progesterone, 280–1
 reversible conditions, 279–81
 ring sideroblasts, 277
- acute intermittent porphyria, 160
- acute leukemia. *See* myelodysplastic syndromes
- adult-onset basal ganglia disease.
 See neuroferritinopathies
- African-American iron overload, 52, 214–17
 clinical description, 214
 dietary and environmental interactions, 215–16
 ferroportin gene mutations, 176
 genetics, 214–15
 iron chelation therapy, 336
 laboratory findings, 216
 non-transfusion iron overload, 214
 prevalence, 216–17
 prevention and treatment, 217
- African iron overload, 36, 52, 211–14
 and tuberculosis, 118
 clinical description, 211
 dietary factors, 212–13
 effects of hepatic disorders, 4
 esophageal cancer risk, 4, 212
 ferroportin gene mutations, 176
 genetics, 211–12
 history, 1–2, 2–3, 211
 iron chelation therapy, 336
 laboratory findings, 213
 prevalence, 211, 213
 prevention and treatment, 213–14
- age
 and penetrance of iron overload, 138
- ALAS2* sideroblastic anemia, 260–6
 clinical description, 260
 genetics, 262–5
 history, 260
 iron overload, 262
 iron overload prevention and treatment, 266
 laboratory findings, 260–2
 prevention and treatment, 265–6
- alcohol intake
 and iron overload, 139
 effects of excess consumption, 28
- alcoholic liver disease, 43, 44
- alcohol-induced sideroblastic anemia, 280
- alcoholism, 4
- aminolevulinate dehydratase deficiency, 160
- ancestral haplotype, 56
 hemochromatosis, 56, 58–9
 HFE C2828Y mutation, 137
- anemia
 heritable forms, 150
 iron-loading anemias, 28
 types associated with iron overload, 51–2
- anti-tuberculosis drugs
 sideroblastic anemia, 279
- antiviral therapy, 44–5
- apoferritin, 11, 37
- apotransferrin, 12, 14
- arthritis, 28
- arthropathy, 4, 75–9
 history, 75–6
 laboratory studies for evaluation of arthritis, 77–9
 natural history, 76–7
 pathophysiology, 76
 physical examination findings, 75–6
 treatment, 79
- ascertainment bias
 definition, 97
- atransferrinemia, 14
 See also acquired atransferrinemia;
 hereditary atransferrinemia
- autosomal dominant hemochromatosis.
 See ferroportin gene (*SLC40A1*) mutations
- azacytidine, 278
- baclofen, 297
- Belgrade rat, 229
- beta-thalassemia
 See also thalassemia syndromes
- bias
 definition, 97
- Blackfan-Diamond syndrome, 115
- blood and bone marrow examination
 technique, 51–3
- blood donation status
 and serum ferritin, 139
- blood lymphocyte subsets
 and iron phenotype, 119
- BMP signaling pathway
 hepcidin expression, 15–16
- BMPs (bone morphogenetic proteins), 15
- bone marrow examination
 technique, 51–3
- Busselton, Australia population
 study, 342
- calcium channel blockers, 332

Index

- calcium homeostasis
 and iron overload, 30
- calreticulin, 16
- cancer chemotherapy
 sideroblastic anemia, 281
- carcinogenesis
 effects of iron overload, 31
- cardiac abnormalities, 69–75
 chelation therapy, 74
 defibrillation, 72–3
 diagnosis of iron-related cardiac disease, 75
 hemochromatosis case study, 69–71
 mechanical support of cardiac output, 74
 physical examination findings, 74–5
 response of cardiac disease to iron depletion, 75
 treatment of iron overload
 cardiomyopathy, 71–2
 treatment of iron-related cardiac disease, 75
- cardiac arrhythmias, 3
- cardiac siderosis, 3, 45
- cardiomyopathy, 3
 in *HAMP* hemochromatosis, 191
 in *HJV* hemochromatosis, 181–6
 in *SLC 40 A1* hemochromatosis, 197
 in thalassemia syndromes, 233–9
 management, 327–8, 330–2
- Ceelen-Gellerstedt syndrome, 319
- cellular organelles
 effects of iron overload, 30–1
- cellular uptake
 non-ferrous metals, 135
- ceruloplasmin, 17
 biochemistry, 284
 copper-binding and transport, 39
 deficiency and iron overload, 39
 iron-related functions, 39
- chemotherapeutic agents
 toxicity related to iron, 31
- chloramphenicol
 sideroblastic anemia, 280
- cobalt absorption/excretion test, 53–4
- complications of hemochromatosis
 and iron overload
 arthropathy, 75–9
 cardiac abnormalities, 69–75
 cutaneous manifestations, 91–4
 diabetes mellitus, 79–84
 evaluation for other hormone disorders, 90–1
 hypogonadism, 84–8
 liver disease, 65–8
 miscellaneous symptoms, 94
 morbidity and mortality, 94–101
 panhypopituitarism, 90–1
- computed tomography (CT)
 scanning, 45
- congenital dyserythropoietic anemia
 general characteristics, 254
 group of disorders, 254
- congenital dyserythropoietic anemia
 type I, 52, 254–6
 clinical course, 255
 clinical manifestations, 254
 genetics, 255
 iron abnormalities, 255
 iron overload treatment, 256
 laboratory abnormalities, 254
 treatment, 255–6
- congenital dyserythropoietic anemia
 type II, 52, 256–8
 clinical course, 256–7
 clinical manifestations, 256
 genetics, 257
 iron overload, 257
 iron overload treatment, 258
 laboratory abnormalities, 256
 treatment, 257–8
- congenital dyserythropoietic anemia
 type III, 52
- congenital erythropoietic porphyria, 160
- congenital non-spherocytic hemolytic anemias, 251
- copper binding and transportation
 ceruloplasmin, 39
- copper deficiency and zinc excess
 sideroblastic anemia, 280
- copper levels in hemochromatosis, 42
- Cunninghamella*, 117
- curcumin, 332
- cutaneous abnormalities, 4
- cutaneous manifestations, 91–4
 cutaneous atrophy, 92
 diagnosis and management, 93
 history, 91
 nails and hands, 92–3
 skin pigmentation, 91–2
See also porphyria cutanea tarda
- cystic fibrosis gene mutations, 127
- cytochrome P-450 enzyme oxidative metabolism, 10
- decitabine, 278
- deferasirox, 5, 248
See also iron chelating drugs
- deferiprone, 4, 248
See also iron chelating drugs
- deferitron, 332
- deferoxamine, 247–8
 and *Yersinia* infection, 118
 history of use in iron overload, 4–5
 urinary iron excretion test, 53
See also iron chelation drugs
- desferrioxamine. *See* deferoxamine
- diabetes mellitus, 28, 79–84
 and iron overload, 3
 complications in hemochromatosis patients, 82
 glucose intolerance in
 hemochromatosis patients, 80–1
 in hemochromatosis patients with cirrhosis, 80–1
 insulin dependence in
 hemochromatosis patients, 80–1
 iron overload in hemochromatosis patients, 81–2
 management in hemochromatosis patients, 83–4
 pathophysiology, 82
 prevalence in hemochromatosis patients, 80
 prevalence of hemochromatosis in persons with, 80
 prognosis for hemochromatosis patients, 84
- diagnosis of hemochromatosis
 early definitions, 139–40
 HLA typing, 140–1
 identification of the *HFE* gene, 141
 non-*HFE* inherited
 hemochromatosis, 141
 OMIM database definitions, 141–2
 phenotypic definition of
 hemochromatosis, 142
 practical approach for
 clinicians, 142
 problems with a genetic
 definition, 142
 segregation analysis, 140
- diagnosis of hemochromatosis
 and iron overload
 history of, 3
- diagnosis of *HFE* hemochromatosis
 using HLA haplotypes, 57
- diagnostic radiology
 conventional techniques, 45–50
- Diesbach, Heinrich, 1

Index

- diet
 government-mandated food fortification with iron, 358–61
 management of iron overload, 336
- dietary iron
 absorption, 10–11
- dietary iron content
 and iron overload penetrance, 138–9
- Dippel, Johann Konrad, 1
- DMT1 (divalent metal transporter-1), 14, 16, 134
 nature and functions, 228
- DMT1 (divalent metal transporter-1)
 iron overload, 228–31
 case descriptions, 228
 clinical description, 228
 family screening, 230
 functions of DMT1, 228
 genetics, 228–30
 laboratory findings, 230
 nature of DMT1, 228
 pathophysiology, 228–30
 treatment, 231
- DNA
 analyses to detect *HFE* C282Y, 153
 damage caused by iron overload, 31
- DNA synthesis, 10
- doxorubicin, 31
- dysmetabolic iron overload syndrome, 36
- ELSI issues. *See* ethical, legal, and social issues (ELSI)
- employment discrimination
 and genetic testing, 347
- endocrine glands
 effects of iron toxicity, 28
- endoplasmic reticulum
 effects of iron overload, 30
- enterocytes
 and iron, 16–17
- erythrocyte measures
 HFE C282Y heterozygotes, 153
- erythrocytapheresis, 248, 328
- erythrocytes
 HFE gene mutation effects, 133
- erythroid cells
 and iron, 18–19
- erythropoiesis, 10
- erythropoiesis disorders
 iron toxicity, 28
- erythropoietic protoporphyria, 160
- Escherichia coli* infections, 116–17
 clinical manifestations, 116
 epidemiology, 116
 treatment, 116–17
- ethical, legal, and social issues (ELSI), 347
 acceptability of genetic testing, 349
 discrimination following genetic testing, 347
 employment discrimination, 347
 genetic counselling, 352
 government-mandated food fortification with iron, 358
 insurance discrimination, 347
 population screening, 350
 use of hemochromatosis blood for transfusion, 355
- excretion
 iron, 10
 non-ferrous metals, 135
- expression of a gene
 definition, 97
- expressivity of a genetic disorder
 definition, 94
- ferritin
 functions, 11
 H (heavy or heart) chains (subunits), 11
 L (light or liver) chains (subunits), 11
 storage of iron, 37
 uptake by hepatocytes, 19–20
 See also serum ferritin
- ferritin heavy-chain gene (*FTH1*) IRE
 mutations, 15, 200–2
 clinical description, 200
 genetics, 200
 laboratory evaluation, 201
 pathophysiology, 200–1
 therapy, 202
- ferritin light-chain gene (*FTL*) IRE
 mutations, 203–8
 characteristics of HHCS, 203
 clinical description, 204–5
 differential diagnosis, 207
 FTL mutation analysis, 205–6
 history of discovery, 203
 laboratory abnormalities, 205
 pathophysiology, 203–4
 population testing, 206–7
 therapy for hereditary hyperferritinemia-cataract syndrome, 207–8
- ferroportin (SLC40A1)
 hepcidin receptor, 16
 IRE regulation, 16
 regulation in macrophages, 20
- ferroportin disease. *See* ferroportin hemochromatosis
- ferroportin hemochromatosis,
 5, 171–7
 and *SLC40A1* mutations, 171
 autosomal dominant inheritance in families, 171
 clinical description, 171
 "gain-of-function" type, 52, 174, 176
 genetics, 171–3
 history, 171
 laboratory evaluation, 174–6
 "loss-of-function" type, 52, 174, 176
 pathophysiology, 173–4
 treatment, 177
- FLCVR heme exporter, 18
- founder effect, 56
- free radical production
 and iron toxicity, 28–30
- Friedreich ataxia, 290–3
 clinical manifestations, 290
 FXN gene mutations, 290–1
 genetics, 290–1
 mitochondrial iron accumulation, 291–2
 pathophysiology, 291–2
 prevalence, 290
 treatment, 292–3
- FTL* gene mutations
 neuroferritinopathies, 301–2
- future research, 364
 biology and genetics of iron homeostasis and iron overload, 364
 complications of iron overload, 366
 diagnosis of hemochromatosis and iron overload, 365
 screening for hemochromatosis and iron overload, 365
 treatment of iron overload, 367
- GDF15 (growth/differentiation factor-15), 18–19, 365
- genetic counselling, 352
- genetic definition of hemochromatosis, 142
- genetic testing
 acceptability of, 349
 employment discrimination, 347
 insurance discrimination, 347
 social issues, 6
- genotype testing
 HFE hemochromatosis, 54–5
 non-*HFE* hemochromatosis, 55–6
 techniques, 54

- GLRX* sideroblastic anemia, 268–9
 clinical description, 268
 genetics, 268–9
 history, 268
 iron overload, 268
 laboratory findings, 268
 treatment, 269
- government-mandated food
 fortification with iron, 358–61
- GRACILE syndrome, 304–6
BCS1 gene mutations, 304–5
 clinical manifestations, 304
 differential diagnosis, 305–6
 genetics, 304–5
 iron accumulation in the liver, 304
 treatment, 306
- HAMP* gene. *See* hepcidin
- HAMP* hemochromatosis, 189–91
 clinical features, 189
 genetics, 189–91
 genotype–phenotype correlations, 191
 laboratory features, 189
 prevention, 191
 treatment, 191
- HARP syndrome, 296
- HCP1 (heme carrier protein-1), 16
- heart
 effects of iron toxicity, 28
- HEIRS Study, 6, 131, 190–1, 344
- Helicobacter pylori* infections, 117
- heme synthesis, 18
- heme–hemopexin complex
 capture by macrophages, 20
 uptake by hepatocytes, 19–20
- hemochromatosis
 and *HFE* mutations, 127–30
 co-inheritance with Wilson's disease, 41
 screening using TS and UIBC, 35–6
 serum ferritin, 38
- hemochromatosis haplotypes, 56–7
- hemochromatosis management
 and non-ferrous metals, 135–6
 nutritional supplements, 135–6
- hemochromatosis type 4.
See ferroportin gene (*SLC40A1*) mutations
- hemoglobin in erythrocytes
 iron pool, 10
- hemoglobin-haptoglobin complex
 capture by macrophages, 20
 uptake by hepatocytes, 19–20
- hemoglobinopathies, 242–8
 and thalassemias, 244
 causes of iron overload, 242
 clinical description of iron overload, 242–3
 evaluation of abnormal hemoglobin or thalassemia, 244
 evaluation of iron overload, 244–5
 evaluation of iron regulatory genes, 245–6
 genetics, 243–4
 geographic distribution, 246–7
 hepcidin expression, 245–6
 history of transfusion treatment, 242
 laboratory findings, 244–6
 prevalence, 246–7
 prevention of iron overload, 247
 transfusion iron overload, 242
 treatment of iron overload, 247–8
- hemojuvelin
 production by hepatocytes, 20
- hemojuvelin (*HJV*) gene mutations, 181–6
 characteristics of juvenile hemochromatosis, 181
 clinical description, 181
 family screening, 184–5
 genetics, 182–4
 history of discovery, 181
 laboratory evaluation, 184
 pathophysiology, 182–4
 treatment of juvenile hemochromatosis, 185–6
- hemosiderin, 11, 37
- HEMPAS (hereditary erythroblastic multinuclearity with positive acidified serum test), 254
- hepatic enzymes
 serum levels in *HFE* C282Y heterozygotes, 152
- hepatic iron concentration (HIC), 43
HFE C282Y heterozygotes, 151
- hepatic iron index (HII), 43
- hepatitis C, 28, 44–5
- hepatocellular carcinoma, 28
 effects of iron overload, 31
 in hemochromatosis, 68
- hepatocytes
 and iron, 19–20
 iron storage, 10
- hepcidin
 effects of anemia, 18
 ferroportin receptor, 16
HAMP gene, 15
- iron storage regulator, 10
 production by hepatocytes, 19–20
 regulation of iron availability, 15
 regulation of plasma and tissue iron levels, 20
 structure and functions, 15
- hepcidin expression
 BMP signaling pathway, 15–16
HFE C282Y heterozygotes, 153
- hepcidin gene (*HAMP*)
 mutations, 189–91
 clinical features, 189
 genetics, 189–91
 genotype–phenotype correlations, 191
 laboratory features, 189
 treatment of *HAMP* hemochromatosis, 191
- hephaestin, 17
- hereditary aceruloplasminemia, 39, 284–8
 age-of-onset, 284–5
 ceruloplasmin biochemistry, 284
 clinical manifestations, 284–5
 differential diagnosis, 286–7
 genetics, 285–6
 genotype–phenotype correlations, 286
 histopathology, 285
 laboratory findings, 285
 MRI, 285, 287
 pathophysiology, 286
 physical examination, 285
 treatment, 287–8
- hereditary atransferrinemia, 36, 52, 222–5
 clinical description, 222
 genetics, 223–4
 genotype–phenotype correlations, 224
 history, 222
 laboratory abnormalities, 222–3
 treatment, 224–5
- hereditary coproporphria, 160
- hereditary hyperferritinemia-cataract syndrome, 1, 5, 203–8
 characteristics, 203
 clinical description, 204–5
 differential diagnosis, 207
FTL mutation analysis, 205–6
 history, 203
 laboratory abnormalities, 205
 pathophysiology, 203–4
 population testing, 206–7
 therapy, 207–8
- hereditary non-spherocytic hemolytic anemia, 251

Index

- hereditary sideroblastic anemias, 260–70
ABCB7 sideroblastic anemia, 266–8
ALAS2 sideroblastic anemia, 260–6
GLRX sideroblastic anemia, 268–9
 iron chelation therapy, 333–4
 mild hypochromic, microcytic anemia, 269
 MLASA, 269
 Pearson marrow-pancreas syndrome, 269
 Rogers syndrome, 269
 TRMA, 269
- hereditary spherocytosis, 51
- HFE* C282Y heterozygosity, 149–55
 and non-*HFE* hemochromatosis, 153
 clinical aspects, 150
 decreased serum ferritin concentration, 151
 definition of heterozygosity, 150
 DNA analyses to detect, 153
 erythrocyte measures, 152–3
 hepatic iron content, 151
 hepcidin expression, 153
 history of the *HFE* C282Y mutation, 149
 laboratory studies, 150–3
 physical examination, 150
 population genetics, 153
 predisposition to various conditions, 153–5
 prevention and treatment of iron overload, 155
 serum iron measures, 150–1
 serum levels of hepatic enzymes, 152
 symptoms and signs, 150
 testing for C282Y, 155
- HFE* C282Y homozygosity
 heterogeneous expression, 58–9
 population screening for, 5
 prevalence of liver disease, 66
- HFE* C282Y mutant protein, 127
- HFE* C282Y mutation, 54, 57, 127–8
 age and origin, 57
 ancestral haplotype, 137
 and porphyria cutanea tarda, 163–4
 discovery of, 5
- HFE* gene
 chromosome 6p location, 56, 57
 identification, 141
- HFE* gene and protein, 127
- HFE* gene expression, 129
- HFE* gene mutation effects
 control of iron absorption, 133–4
- iron absorption, 131–2
 iron and erythrocytes, 133
 iron deposition in target organs, 132–3
 iron transport, 132
 penetrance of hemochromatosis, 134
- HFE* gene mutations
 and hemochromatosis, 127–30
 and heritable iron overload, 127
 and thalassemia syndromes, 234–6
 “classical” hemochromatosis, 127
 discovery of, 5
 genotype testing, 54–5
 molecular genetics, 127
 mouse models, 129
 number of mutations, 127
 population genetics, 130–1
 prevalence, 130–1
 prevalence in hemochromatosis patients, 131
 rare mutations, 129
 testing for, 155
- HFE* gene mutations and iron overload
 age and penetrance, 138
 ancestral haplotype, 137
 effects of dietary iron content, 138–9
 genotypic factors affecting penetrance, 137–8
 non-genetic factors, 138–9
 penetrance, 136–7
 phenotype heterogeneity, 136
 sex differences, 138
 variability in penetrance, 137
 variable expression of iron overload, 136–9
- HFE* gene regulation, 129
- HFE* H63D mutation, 54, 127, 129
 and porphyria cutanea tarda, 163–4
 discovery of, 5
- HFE* hemochromatosis, 1
 blood examination, 52
 damage caused by iron toxicity, 28
 differential diagnosis, 287
 iron chelation therapy, 334–5
 mouse models, 129
 screening using TS and UIBC, 35–6
 serum ferritin, 38
 severity in the ancestral haplotype, 58–9
 staging, 65–6
 TS and TIBC measures, 35
- HFE* protein
 effect on iron metabolism, 129–30
- HFE* S65C mutation, 54
- HIF
 role in regulating gene expression, 18
- history of iron overload disorders, 1–6
 characterisation of iron overload disorders, 1–2
 complications of iron overload, 3–4
 detecting iron in tissue, 1
 diagnosis of hemochromatosis and iron overload, 3
 discovery of *HFE* gene mutations, 5
 discovery of HLA link with hemochromatosis, 5
 discovery of Prussian blue, 1
 genetic basis of iron overload disorders, 5
 iron and immunity, 4
 iron overload in non-European peoples, 1–2, 2–3
 Perls’ technique for histologic analysis of iron, 1
 population screening for hemochromatosis and iron overload, 5
 possible causes, 2–3
 social issues with genetic testing, 6
 treatment and outcomes, 4–5
 use of oral iron chelators, 4–5
 use of phlebotomy, 4
- HLA (human leukocyte antigen)
 discovery of link with hemochromatosis, 5
- HLA gene polymorphisms, 56
- HLA haplotypes, 56
- HLA typing, 140–1
 in *HFE* hemochromatosis, 56–9
- humoral immunity, 119–20
- hypogonadism, 84–8
 classification, 84–5
 endocrine and heart failure syndrome, 87
 in *HAMP* hemochromatosis, 189, 191
 in *HJV* hemochromatosis, 181–2, 184, 186
 in *TFR2* hemochromatosis, 193–7
 in thalassemia syndromes, 236
 laboratory diagnosis, 87
 pathology, 85–6
 pathophysiology, 86–7
 treatment, 87–8, 327
- hypogonadotrophic hypogonadism, 3, 28, 85
- idebenone, 292
- immunity, 118–20
 and iron overload, 4

- blood lymphocyte subsets and iron phenotype, 119
- humoral immunity, 119–20
- monocytes and macrophages, 118–19
- neutrophils, 118
- phagocytes, 118–19
- immunosuppressive drugs
 - sideroblastic anemia, 281
- incidence
 - definition, 97
- infections, 112–18
 - and iron overload, 4
 - Escherichia coli* infections, 116–17
 - Helicobacter pylori* infections, 117
 - Listeria monocytogenes* infections, 116
 - other bacterial infections, 117
 - susceptibility in hemochromatosis and iron overload, 112
 - tuberculosis, 118
 - Vibrio vulnificus* infections, 112–15
 - viral hepatitis, 117–18
 - Yersinia* species infections, 115–16
 - zygomycosis, 117
- insulin resistance syndrome
 - and non-alcoholic fatty liver disease, 108
 - clinical manifestations, 108–9
 - current diagnostic criteria, 109
 - general management, 109–10
 - incidence, 108
 - iron depletion, 110
 - risk factors, 108
 - treatment, 109–10
- insurance discrimination
 - and genetic testing, 347
- interferon, 45
- intracellular iron homeostasis, 14–15
- IREs (iron-responsive/regulatory elements)
 - biochemistry, 14–15
 - in ferritin heavy-chain iron overload, 200–2
 - in hereditary hyperferritinemia-cataract syndrome, 203–10
- iron absorption, 11–14
 - and *HFE* mutations, 131–2
 - control in hemochromatosis, 133–4
 - methods to decrease, 336
- iron and erythrocytes
 - HFE* gene mutation effects, 133
- iron and specific cells
 - enterocytes, 16–17
 - erythroid cells, 18–19
 - hepatocytes, 19–20
 - Kupffer cells, 20
 - macrophages, 20
- iron binding and transportation, 11–14
- iron chelation drugs, 4–5, 247–8, 330–2
- iron chelation therapy, 328–36
- iron deposition in target organs, 132–3
- iron homeostasis, 11–16
 - intracellular iron homeostasis, 14–15
 - iron procurement, 11–14
 - iron storage, 11
 - regulation of iron availability, 15–16
- iron loss mechanisms, 10
- iron overload disorders
 - serum ferritin, 38
- iron phenotype
 - and blood lymphocyte subsets, 119
- iron physiology, 10–11
- iron pools in the body
 - hemoglobin in erythrocytes, 10
 - hepatocytes and macrophages, 10
 - myoglobin, 10
- iron procurement, 11–14
- iron responsive/regulatory elements. *See* IREs
- iron toxicity, 4, 28–32
 - carcinogenesis, 31
 - cellular organelle dysfunction, 30–1
 - consequences of excess iron deposition, 28
 - disorders of erythropoiesis, 28
 - DNA damage, 31
 - effects on endocrine glands, 28
 - effects on endoplasmic reticulum, 30
 - effects on plasma membranes, 30–1
 - effects on the heart, 28
 - effects on the liver, 28
 - free radical production, 28
 - HFE* hemochromatosis, 28
 - lysosomal injury hypothesis, 30
 - mitochondrial dysfunction, 30
 - oxidative injury hypothesis, 28–30
 - proposed mechanisms, 31–2
- iron transport
 - and *HFE* mutations, 132
- IRPs (iron-responsive/regulatory proteins), 14–15
- juvenile hemochromatosis, 3, 181–6
 - and hemojuvelin (*HJV*) gene mutations, 181
 - characteristics, 181
 - clinical description, 181
 - family screening, 184–5
 - first description, 1
 - genetics, 182–4
 - history, 181
 - laboratory evaluation, 184
 - pathophysiology, 182–4
 - treatment, 185–6
- Kaiser Permanente, California health appraisal clinic study, 344
- Kearns–Sayre syndrome, 274, 275
- Kupffer cells
 - and iron, 20
 - iron storage, 10
- L1Nall, 332
- lactoferrin
 - iron binding, 20
 - uptake by hepatocytes, 19–20
- lead intoxication
 - sideroblastic anemia, 279–80
- legal issues. *See* ethical legal and social implications (ELSI)
- Leigh syndrome, 274, 275
- lenalidomide, 278
- lipid peroxidation
 - iron toxicity, 28–30
- Listeria monocytogenes* infections, 116
 - clinical manifestations, 116
 - epidemiology, 116
 - treatment, 116
- liver
 - effects of iron overload, 3
 - effects of iron toxicity, 28
- liver biopsy, 43–5
- liver disease
 - diagnosis in hemochromatosis, 66–7
 - hepatocellular carcinoma in hemochromatosis, 68
 - iron and *HFE* mutations in non-hemochromatosis disease, 67–8
 - iron-induced, 66
 - prevalence in C282Y homozygotes, 66
- liver iron deposition
 - effects of hepatic disorders, 4
- localized iron overload
 - pulmonary hemosiderosis, 319
 - renal hemosiderosis, 319
- lysosomal injury hypothesis of iron toxicity, 30
- MacDonald, Richard A, 2–3
- macrocytosis, 52

Index

- macrophages
 and iron, 20
 in bone marrow specimens, 52
 iron storage, 10
- magnetic resonance imaging (MRI),
 3, 46–7
 detection of primary liver
 cancer, 48–9
 iron overload disorders, 47
 quantitative iron measurements,
 49–50
- management of iron overload,
 321–37
 aims, 321
 diet, 336
 erythrocytapheresis, 328
 iron chelation therapy, 328–36
 methods to decrease absorption, 336
 therapeutic phlebotomy, 321–8
- Melbourne, Australia collaborative
 cohort study, 345
- Menke disease, 287
- metabolic syndrome. *See* insulin
 resistance syndrome
- microcytic anemia mouse, 229
- mild hypochromic, microcytic
 anemia, 269
- mitochondria
 dysfunction cause by iron
 toxicity, 30
 heme synthesis, 18
- mitochondrial DNA deletions.
See Pearson marrow-pancreas
 syndrome
- mitochondrial mutations
 as modifiers of iron overload, 169
 mitochondrial DNA 16189
 variant, 169
- mitochondrial myopathy and
 sideroblastic anemia
 (MLASA), 269
- mitoferrin, 18, 169
- morbidity of hemochromatosis, 97–100
- mortality of hemochromatosis, 100–1
- mouse models
HFE hemochromatosis, 129
 microcytic anemia (*mk*) mouse, 229
- mRNA
 IREs, 14–15
- mucormycosis, 117
- myelodysplasia, 53
- myelodysplastic syndromes
 acquired sideroblastic anemia, 277–9
 classification, 277
 clinical features, 277–8
 iron chelation therapy, 334
 iron overload, 278–9
 laboratory features, 278
 management, 278–9
 pathophysiology, 277
- myoglobin
 iron pool, 10
- necrotizing fasciitis, 114
- neonatal hemochromatosis, 308–11
 clinical description, 308
 genetics, 310
 history, 308
 iron deposition in the liver, 308
 laboratory findings, 308–9
 liver injury and dysfunction, 308
 possible causes, 308
 prevention and treatment, 310–11
- nephrotic syndrome
 acquired atransferrinemia, 225
- neurodegeneration with brain iron
 accumulation. *See* pantothenate
 kinase-associated
 neurodegeneration
- neuroferritinopathies, 299–302
 brain iron accumulation, 301
 brain MRI, 301
 clinical description, 299–300
FTL gene mutations, 301–2
 genetics, 301
 genotype–phenotype correlations,
 301–2
 history, 299
 laboratory abnormalities, 300–1
 treatment, 302
- neuroferritinopathy, 38
- neutrophils, 118
- nifedipine, 231
- non-alcoholic fatty liver disease
 (NAFLD), 43, 44
 and insulin resistance, 108
- non-ferrous metals
 absorption, 134
 and hemochromatosis
 management, 135–6
 cellular uptake, 135
 excretion, 135
 organ distribution and storage, 135
 transport in blood, 134–5
- non-genetic factors in iron overload
 penetrance, 138–9
- non-*HFE* hemochromatosis
 and *HFE* C282Y heterozygosity, 153
 and HLA haplotypes, 59
 genotype testing, 55–6
 iron chelation therapy, 335–6
- non-*HFE* inherited
 hemochromatosis, 141
- non-transferrin bound iron (NTBI)
 cellular injury, 12
 entry into hepatocytes, 19
- Nord-Trøndelag County, Norway
 health survey program, 344
- normal iron absorption and
 metabolism, 10–20
 dietary iron absorption, 10–11
 functions of erythroid cells,
 18–19
 functions of hepatocytes, 19–20
 functions of macrophages, 20
 intracellular iron homeostasis,
 14–15
 iron homeostasis, 11–16
 iron loss mechanisms, 10
 iron physiology, 10–11
 iron pools in the body, 10
 iron procurement, 11–14
 iron storage, 11
 regulation of iron availability, 15–16
 role of enterocytes, 16–17
- observer bias
 definition, 97
- Online Mendelian Inheritance in
 Man (OMIM) database
 forms of heritable
 hemochromatosis, 141–2
- organ distribution and storage
 non-ferrous metals, 135
- oxidative injury hypothesis of iron
 toxicity, 28–30
- panhypopituitarism, 90–1
 diagnosis, 90
 thyroid disease, 88–90
- PANK2* gene mutations, 296
- pantothenate kinase-associated
 neurodegeneration, 294–7
 brain imaging, 296
 clinical manifestations, 294–5
 differential diagnosis, 296
 genotype–phenotype correlations, 296
 iron accumulation in the brain, 295
PANK2 gene mutations, 296
 pathophysiology, 295
 prevalence, 294
 treatment, 296–7

Index

- Pearson marrow-pancreas syndrome, 269, 274–6
 clinical manifestations, 274
 differential diagnosis, 275
 genetics, 275
 laboratory findings, 274
 mitochondrial DNA deletions, 275
 treatment, 275–6
- penetrance of hemochromatosis, 94, 99–100, 134, 136
- Perls' technique for histologic analysis of iron, 1
- Perls, Max, 1
- Perls' Prussian blue stain for liver biopsy, 43
- phagocytes, 118–19
- phenotypic definition of hemochromatosis, 142
- phlebotomy
 history of use in iron overload, 4
 management of iron overload, 321–8
 quantitative, 50–1
 therapeutic phlebotomy, 321–8
- plasma membrane
 effects of iron overload, 30–1
- population genetics
HFE C282Y heterozygosity, 153
- population screening for hemochromatosis, 5, 342
 ethical, legal, and social implications, 350
 large-scale screening programs, 342
 population screening versus targeted screening, 345
- porphyria
 types and characteristics, 160
- porphyria cutanea tarda, 93–4, 160
 blood tests of iron stores, 163
 clinical manifestations, 161–2
 elevated liver enzymes, 163
 familial or type II, 160
 function of URO-D, 162
 genetics, 162
 laboratory findings, 163–4
 outbreaks or clusters, 161
 pathology, 162
 pathophysiology, 162–3
 physical examination findings, 161–2
 porphyria types and characteristics, 160
 presence of *HFE* mutations, 163–4
 prevalence, 160
 role of URO-D (uroporphyrinogen decarboxylase), 160–1
- skin fluorescence, 162
 sporadic or type I, 160
 type III, 160–1
 types of, 160–1
 urinary excretion of porphyrins, 163
UROD gene mutations, 162
 viral hepatitis C infection, 163
- porphyria cutanea tarda treatment, 165–6
 and anastrozole therapy, 166
 and transdermal estrogen replacement, 166
 chloroquine therapy, 166
 oral iron chelation, 166
 phlebotomy, 165–6
- prevalence
 definition, 97
- progesterone
 acquired sideroblastic anemia, 280–1
- prohepcidin, 153
- Prussian blue
 discovery of, 1
- pulmonary hemosiderosis, 319
- pyruvate kinase deficiency, 52, 251–2
 clinical manifestations, 251
 etiology, 251
 etiology of iron overload, 252
 genetics, 252
 hereditary non-spherocytic hemolytic anemia, 251
 iron overload, 251, 252
 laboratory findings, 251
 management of iron overload, 252
 pathogenesis, 251
PKLR gene mutations, 252
 prevalence, 251
- quantitative phlebotomy, 50–1
- refractory anemia with excess blasts, RAEB. *See* myelodysplastic syndromes
- refractory anemia with ring sideroblasts (RARS). *See* myelodysplastic syndromes
- refractory cytopenias with multilineage dysplasia and ring sideroblasts (RCMD-RS). *See* myelodysplastic syndromes
- renal hemosiderosis, 319
- ribavirin, 45
- ringed sideroblasts, 53
- Rochester, New York primary care patients study, 342
- Rogers syndrome, 269
- segregation analysis, 140
- serum ceruloplasmin test, 39–42
- serum ferritin, 37–9
 hemochromatosis and iron overload disorders, 38
HFE heterozygotes, 151
 normal subjects, 37–8
 screening for iron overload, 38–9
- serum iron measures
HFE C282Y heterozygotes, 150–1
- sex differences
 iron overload penetrance, 138
- Sheldon, Joseph H., 2–3
- sickle cell disease, 115
See hemoglobinopathies
 iron chelation therapy, 333
- sideroblastic anemia, 28, 51–2, 52–3, 169
See also acquired sideroblastic anemias; hereditary sideroblastic anemias
- siderosomes, 18
- SLC40A1* mutations. *See* ferroportin gene (*SLC40A1*) mutations
- social issues. *See* ethical legal and social implications (ELSI)
- spherocytosis, 150
- SQUID (superconducting quantum interference device), 3, 50
- staging of *HFE* hemochromatosis, 65–6
- Staphylococcus aureus*, 118
- starch deferoxamine polymers, 332
- STAT, 15
- STEAP ferrioreductase, 14, 16
- STEAP1, 20
- STEAP3, 20
- Strachan, AS, 1–2, 2–3, 4
- Streptococcus pyogenes*, 114
- supplements
 hemochromatosis patients, 135–6
- supplements and iron overload, 313–17
 excessive oral iron supplements, 313–14
 excessive parenteral iron-carbohydrate complexes, 314–17
 iron chelation therapy, 336

Index

- tests for hemochromatosis and iron overload
 - blood and bone marrow examination technique, 51–3
 - cobalt absorption/excretion test, 53–4
 - conventional diagnostic radiology techniques, 45–50
 - deferoxamine-induced urinary iron excretion, 53
 - genotype testing, 54–6
 - HLA typing in *HFE* hemochromatosis, 56–9
 - liver biopsy, 43–5
 - quantitative phlebotomy, 50–1
 - serum ceruloplasmin, 39–42
 - serum ferritin, 37–9
 - SQUID, 50
 - transferrin and transferrin saturation (TS), 34–7
- TFR1 (transferrin receptor-1), 12
 - hepatocytes, 19
- TFR2 (transferrin receptor-2)
 - hepatocytes, 19
- TFR2* hemochromatosis, 193–7
 - characteristics, 193
 - gene mutations, 194–7
 - genetics, 194–7
 - history, 193
 - laboratory findings, 193–4
 - prevention and treatment, 197
- thalassemia syndromes, 233–9
 - and hemoglobinopathies, 244
 - and *HFE* mutations, 234–6
 - chronic erythrocyte transfusion, 234
 - clinical manifestations, 236
 - development of iron overload, 233–4
 - effects of iron overload, 233, 236
 - effects of thalassemia phenotypes, 234
 - GDF15 overexpression, 233
 - iron chelation therapy, 332–3
 - management of iron overload, 236–9
 - mechanisms that enhance iron absorption, 233
 - nature of thalassemias, 233
 - TWSG1 (twisted gastrulation) expression, 233
 - use of oral iron chelators, 4–5
 - β -thalassemia, 28, 51, 115
- thiamine-responsive megaloblastic anemia syndrome (TRMA), 269
- thyroid disease, 88–90
 - diagnosis of thyroid disorders, 88–9
 - hypothyroidism in hemochromatosis homozygote screening studies, 88
 - hypothyroidism in iron-loaded hemochromatosis patients, 88
 - prevalence, 88
 - treatment, 89–90
- TIBC (total iron-binding capacity)
 - definition, 34
 - HFE* hemochromatosis, 35
 - normal subjects, 34–5
- transferrin
 - iron-binding and transportation, 11–14, 34
 - transport of non-ferrous metals, 134–5
- transferrin saturation (TS), 12
 - definition, 34
 - HFE* hemochromatosis, 35
 - non-*HFE* hemochromatosis and iron overload, 36–7
 - normal subjects, 34–5
 - screening for hemochromatosis, 35–6
- transfusion
 - effect on transferrin saturation, 36
 - use of hemochromatosis blood, 355
- transfusion iron overload, 52, 242
 - clinical description, 242–3
- trihexyphenidyl, 297
- tuberculosis, 4
 - and iron overload, 118
- UIBC (unbound iron-binding capacity)
 - definition, 34
 - screening for hemochromatosis, 35–6
- URO-D (uroporphyrinogen decarboxylase)
 - function, 162
 - role in porphyria cutanea tarda, 160–1
- URO-D function, 162
- UROD* gene mutations, 162
- Utah blood donors study, 342
- variegate porphyria, 160
- Vibrio alginolyticus*, 114
- Vibrio cholerae*, 114
- Vibrio parahaemolyticus*, 114
- Vibrio vulnificus* infections, 112–15
 - and iron in blood, 113–14
 - clinical manifestations, 112–13
 - epidemiology, 112
 - necrotizing fasciitis, 114
 - prevention, 114, 337
 - treatment, 114–15
- viral hepatitis, 4, 43, 44, 117–18
- Virchow, Rudolph, 1
- wheat grass, 332
- Wilson disease, 40
 - ceruloplasmin deficiency, 39
 - co-inheritance with hemochromatosis, 41
 - differential diagnosis, 287
 - hepatic iron levels, 40
- X-linked sideroblastic anemia, 1, 5, 36, 52, 270
 - See also* hereditary sideroblastic anemias
- Yersinia* species infections, 115–16
 - and iron chelation therapy, 115
 - clinical manifestations, 115
 - role of neutrophils, 118
 - treatment, 115–16
- zebrafish *shiraz* mutants, 268
- zinc excess and copper deficiency sideroblastic anemia, 280
- zygomycosis, 117
 - clinical manifestations, 117
 - epidemiology, 117
 - treatment, 117